Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gritstone, Gilead Partner To Develop Therapeutic HIV Vaccine

Deal Closely Follows COVID-19 Vaccine Effort

Executive Summary

Gritstone will supply the same type of prime-boost vaccine technology it is applying to SARS-CoV-2, and Gilead will supply its own antigens, with the goal of curing HIV.

You may also be interested in...



A HIV Vaccine Proves Elusive Again As J&J Study Fails

Another vaccine failure shows that HIV’s ability to “attack, hijack and evade” the human immune system is still outwitting researchers, but J&J will continue with Phase III study of a related vaccine.

As Gilead’s HIV, HCV Hull Leaks In Q4, Veklury Plugs Holes

Sales of COVID-19 drug Veklury helped keep sales in the black as the pandemic and generic competition weighed on HIV and HCV products; Gilead raised full-year 2021 guidance.

Deal Watch: Genentech Gets Access To X-Chem’s DNA-Encoded Library Technology

Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel